Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 2, 2006, Pages 169-174

  Chern, Chang Ming ^a   Hsu, Hung Yi ^b   Hu, Han Hwa ^a   Chen, Yen Yu ^a   Hsu, Li Chi ^a   Chao, A Ching ^c,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Atenolol; Baroreflex sensitivity; Essential hypertension; Heart rate variability; Losartan

Indexed keywords

ATENOLOL; CREATININE; LOSARTAN POTASSIUM; NITROGEN; UREA; ANTIHYPERTENSIVE AGENT; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; FOURIER TRANSFORMATION; HEART RATE; HEART RATE VARIABILITY; HUMAN; MALE; MONOTHERAPY; PLETHYSMOGRAPHY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; BLOOD PRESSURE; COMPARATIVE STUDY; FOLLOW UP; HYPERTENSION; MIDDLE AGED; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BAROREFLEX; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746413031     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000199225.17928.f5     Document Type: Article

References (42)

1. Esler M. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens. 1989;2:S140-S146.
2. Yamori Y. Neurogenic mechanisms of spontaneous hypertension. In Onesti G, Fernandes M, Kim KE (eds). Regulation of Blood Pressure by the Central Nervous System. New York: Grune and Stratton Inc; 1975: 65-76.
3. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996;93:1043-1065.
4. Parati G, Di Rienzo M, Mancia G. How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens. 2000;18:7-19.
5. Schroeder EB, Liao D, Chambless LE, et al. Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension 2003;42:1106-1111.
6. Ylitalo A, Airaksinen J, Tahvanainen K, et al. Baroreflex sensitivity in drug-treated systemic hypertension. Am J Cardiol. 1997;80:1369-1372.
7. Mussalo H, Vanninen E, Ikaheimo R, et al. Baroreflex sensitivity in essential and secondary hypertension. Clin Auton Res. 2002;12:465-471.
8. Sevre K, Lefrandt JD, Nordby G, et al. Autonomic function in hypertensive and normotensive subjects: the importance of gender. Hypertension 2001;37:1351-1356.
9. Huikuri HV, Ylitalo A, Pikkujamsa SM, et al. Heart rate variability in systemic hypertension. Am J Cardiol. 1996;77:1073-1077.
10. Fagard RH, Pardaens K, Staessen JA. Relationships of heart rate and heart rate variability with conventional and ambulatory blood pressure in the population. J Hypertens. 2001;19:389-397.
11. Singh JP, Larson MG, Tsuji H, et al. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension 1998;32:293-297.
12. La Rovere M, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998;351:478-484.
13. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (U.K.-heart). Circulation. 1998;98:1510-1516.
14. La Roverre MT, Pinna GD, Hohnlose HS, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias. Implications for Clinical Trials. Circulation. 2001;103:2072-2077.
15. Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events: the Framingham Heart Study. Circulation. 1996;94:2850-2855.
16. Parati G, Mutti E, Frattola A, et al. Beta-adrenergic blocking treatment and 24-hour baroreflex sensitivity in essential hypertensive patients. Hypertension 1994;23:992-996.
17. Lucini D, Pagani M, Malliani A. Improved baroreflex control of the heart rate with chronic beta-adrenergic blockade in mild hypertension. J Hypertens. 1993;(Suppl 11):S156-S157.
18. Chen X, Hassan MO, Jones JV, et al. Baroreflex sensitivity and the blood pressure response to beta-blockade. J Hum Hypertens. 1999;13:185-190.
19. Floras JS, Hassan MO, Jones JV, et al. Factors influencing blood pressure and heart rate variability in hypertensive humans. Hypertension 1988;11:273-281.
20. Lucini D, Pagani M, Mela GS, et al. Sympathetic restraint of baroreflex control of heart period in normotensive and hypertensive subjects. Clin Sci. 1994;86:547-556.
21. Parati G, Pomidossi G, Grassi G, et al. Mechanisms of antihypertensive action of beta-adrenergic blocking drugs: evidence against potentiation of baroreflexes. Eur Heart J. 1983;4:19-25.
22. Lantelme P, Khettab F, Gustaud M-A, et al. Spontaneous baroreflex sensitivity: toward an ideal index of cardiovascular risk in hypertension? J Hypertens. 2002;20:934-944.
23. Kohara K, Hara-Nakamura N, Hiwada K. Left ventricular mass index negatively correlates with heart rate variability in essential hypertension. Am J Hypertens. 1995;8:183-188.
24. Mandawat MK, Wallbridge DR, Pringle SD, et al. Heart rate variability in left ventricular hypertrophy. Br Heart J. 1995;73:139-144.
25. Head GA. Baroreflex and cardiovascular regulation in hypertension. J Cardiovasc Pharmacol. 1995;26(Suppl 2):S7-S16.
26. Ylitalo A, Airaksinen KE, Sellin L, et al. Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension. Am J Cardiol. 1999;83:885-889.
27. Amador N, Encarnacion JJ, Guizar JM, et al. Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomised trial. J Hum Hypertens. 2005;19:277-283.
28. Guasti L, Petrozzino MR, Mainardi LT, et al. Autonomic function and baroreflex sensitivity during angiotensin-converting enzyme inhibition or angiotensin II AT-1 receptor blockade in essential hypertensive patients. Acta Cardiol. 2001;56:289-295.
29. Fridman KU, Wysocki M, Friberg PR, et al. Candesartan cilexetil in hypertension: effects of six-weeks' treatment on haemodynamics, baroreceptor sensitivity and the rennin-angiotensin-aldosterone system. Blood Press. 1999;8:242-247.
30. Yee KM, Struthers AD. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man. Br J Clin Pharmacol. 1998;46:583-588.
31. Rongen GA, Brooks SC, Ando S, et al. Neural and hypotensive effects of angiotensin II receptor blockade. Hypertension 1998;31(1 part 2):378-383.
32. Heusser K, Vitkovsky J, Schmieder RE, et al. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci-Basic Clin. 2003;107:45-51.
33. Munakata M, Aihara A, Nunokawa T, et al. The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension-comparison with calcium channel blockers. Clin Exp Hypertens. 2003;25:169-181.
34. Ylitalo A, Airaksinen KE, Tahvanainen KU, et al. Baroreflex sensitivity in drug-treated systemic hypertension. Am J Cardiol. 1997;80:1369-1372.
35. Dahlöf B, Devereus RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
36. Jern S. Assessment of left ventricular hypertrophy in patients with essential hypertension. Blood Pressure 1997;6(Suppl 2):16-23.
37. Kuo TBJ, Yien HW, Hseu SS, et al. Diminished vasomotor component of systemic arterial pressure signals and baroreflex in brain death. Am J Physiol. 1997;273:H1291-H1298.
38. James MA, Paneral RB, Potter JF. Applicability of new techniques in theassessment of arterial baroreflex sensitivity in the elderly: a comparison with established pharmacological methods. Clin Sci. 1998;94:245-253.
39. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
40. Donmez G, Derici U, Erbas D, et al. The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol. 2002;52:434-440.
41. Chowdhary S, Townend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor! J Hum Hypertens. 2001;15:219-227.
42. Chowdhary S, Vaile JC, Fletcher J, et al. Nitric oxide and cardiac autonomic control in humans. Hypertension 2000;36:264-269.